ArticleJournal of pain research2025
Effectiveness and Safety of Platelet-Rich Plasma Combined with Pulsed Radiofrequency to Treat Patients with Infraorbital Neuralgia: A Propensity Score-Matched Analysis of a Multi-Center, Prospective Cohort Protocol.
Article in Journal of pain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infraorbital neuralgia (IONa) is a rare but devastating type of facial pain, with a lack of current consensus on its proper management. Preliminary studies have established the efficacy of pulsed radiofrequency (PRF) in the treatment of IONa. Platelet-rich plasma (PRP) is a non-destructive technique that alleviates neuropathic pain. Till date, the efficacy of PRP combined with PRF in the treatment of IONa has not been evaluated yet. Objective: To evaluate the efficacy and safety of PRP combined with PRF in treating refractory IONa in patients unwilling to undergo destructive therapies. Study Design: A multicenter, prospective, observational, propensity score matching (PSM), and assessor-blinded study. Setting: Department of pain management in Beijing, Wuhan and Qingdao, China. Methods: A total of 240 refractory IONa patients will be allocated to either PRP combined with PRF therapy (PRP+PRF) group or PRF therapy alone (PRF) group at their own volition. Statistical analysis will be performed using Pearson's chi-squared or Fisher's exact test for categorical variables, Student's Results: The primary outcome will be the 12-months response rate. The secondary outcome will include NRS score, total daily dose of carbamazepine, the 12-item Short-Form Health Survey (SF-12) scores, patient satisfaction scores (PSS) and adverse events (AEs). Limitation: This is an observational, open-labeled study with a relatively short term follow-up. The composition of PRP and various cell ratios, which are optimal for IONa has not been published yet. Conclusion: This will be a multi-center trial with a relatively large sample size, demonstrating the potential benefits of PRP combined with PRF therapy in IONa patients. Further, randomized controlled trial (RCT) will be necessary to confirm the efficacy of this combined therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.